

**BEFORE THE
BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

In the Matter of the Accusation Against:

**GSL PHARMACY, INC., DBA PLAZA WEST PHARMACY,
YELENA GOLDINA, CHIEF EXECUTIVE OFFICER
Pharmacy Permit No. PHY 50644,**

and

**YELENA GOLDINA
Pharmacist License No. RPH 51771,**

Respondents.

Agency Case No. 7431

OAH NO. 2023080264

DECISION AND ORDER

The attached Stipulated Settlement for Withdrawal of Accusation and Issuance of Citation is hereby adopted by the Board of Pharmacy, Department of Consumer Affairs, as its Decision in this matter.

This Decision shall become effective at 5:00 p.m. on June 19, 2024.

It is so ORDERED on May 20, 2024.

BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

By

A handwritten signature in black ink, appearing to read "Seung W. Oh". The signature is fluid and cursive, with the first name "Seung" and last name "Oh" clearly visible.

Seung W. Oh, Pharm.D.
Board President

1 ROB BONTA
Attorney General of California
2 THOMAS L. RINALDI
Supervising Deputy Attorney General
3 HEATHER VO
Deputy Attorney General
4 State Bar No. 223418
300 So. Spring Street, Suite 1702
5 Los Angeles, CA 90013
Telephone: (213) 269-6317
6 Facsimile: (916) 731-2126
Attorneys for Complainant
7

8 **BEFORE THE**
9 **BOARD OF PHARMACY**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 7431

13 **GSL PHARMACY, INC., dba**
14 **PLAZA WEST PHARMACY**
15 **YELENA GOLDINA, Chief Executive Officer**
8540 Sepulveda Blvd, #102
Los Angeles, CA 90045

OAH No. 2023080264

**STIPULATED SETTLEMENT FOR
WITHDRAWAL OF ACCUSATION
AND ISSUANCE OF CITATION**

16 **Pharmacy Permit No. PHY 50644**

17 **and**

18 **YELENA GOLDINA**
19 **8540 Sepulveda Blvd., #102**
Los Angeles, CA 91436

20 **Pharmacist License No. RPH 51771**

21 Respondents.

22
23 IT IS HEREBY STIPULATED AND AGREED by and between the parties to the above-
24 entitled proceedings that the following matters are true:
25
26
27
28

1 **PARTIES**

2 1. Anne Sodergren (Complainant) is the Executive Officer of the Board of Pharmacy
3 (Board). She brought this action solely in her official capacity and is represented in this matter by
4 Rob Bonta, Attorney General of the State of California, by Heather Vo, Deputy Attorney General.

5 2. GSL Pharmacy, Inc., doing business as Plaza West Pharmacy (Respondent Plaza
6 West Pharmacy) and Yelena Goldina (Respondent Goldina) are represented in this proceeding by
7 attorney Ivan Petrzelka, Esq., whose address is: 9090 Irvine Center Drive, Irvine, CA 92618-
8 4658.

9 **Pharmacy Permit**

10 3. On or about June 9, 2011, the Board of Pharmacy issued Pharmacy Permit Number
11 PHY 50644 to Respondent Plaza West Pharmacy. The Pharmacy Permit was in full force and
12 effect at all times relevant to the charges brought herein and will expire on June 1, 2024, unless
13 renewed.

14 **Pharmacist License**

15 4. On or about August 29, 2000, the Board of Pharmacy issued Pharmacist License
16 Number RPH 51771 to Respondent Goldina. The Pharmacist License was in full force and effect
17 at all times relevant to the charges brought herein and will expire on July 31, 2024, unless
18 renewed. Respondent Goldina has been the Pharmacist-in-Charge of Respondent Plaza West
19 Pharmacy since October 1, 2013.

20 **JURISDICTION**

21 5. Accusation No. 7431 was filed before the Board, and is currently pending against
22 Respondents. The Accusation and all other statutorily required documents were properly served
23 on Respondents on April 21, 2023. Respondents timely filed their Notice of Defense contesting
24 the Accusation.

25 6. A copy of Accusation No. 7431 is attached as exhibit A and incorporated herein by
26 reference.

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28

- 2
- 3
- 4
- 5

6
7
8
9
10
11

12
13

14

15
16

17
18
19

20
21
22
23
24
25

26

RESOLUTION

14. Complainant shall withdraw the Accusation No. 7431 and in its place, issue a citation to Respondents under Business and Professions Code section 125.9 on the following terms.

- (A) Respondents Plaza West Pharmacy and Goldina shall be cited for violating Business and Professions Code section 4081(a) [failure to maintain current inventory of dangerous drugs and failure to maintain records of dangerous drugs];
- (B) The citation shall charge that the violations were based on a Board audit for medications dispensed between January 1, 2020 and December 30, 2021 for the following drugs: Creon Dr 24,000 units capsule, Dexilant Dr 60 mg capsule, Vascepa 1 gm capsule, Xarelto 15 mg tablet, and Xarelto 20 mg tablet.
- (C) The Board reviewed the pharmacy's dispensing records, stock on hand, and wholesaler records. Based on the evidence collected, the audit revealed that Respondent Plaza West Pharmacy sold a greater amount of medication than it purchased with respect to each of the aforementioned drugs, resulting in an overpayment by insurance providers to Respondent Plaza West Pharmacy;
- (D) As to Respondent Plaza West Pharmacy, the citation shall carry an administrative fine of \$5,000.00 due 30 days after the citation's issuance;
- (E) As to Respondent Goldina, the citation shall carry an administrative fine of \$5,000.00 due 30 days after the citation's issuance;
- (F) The citation shall carry cost recovery for prosecution and investigative costs of \$5,000.00 and shall be paid within one year after the citation's issuance; and
- (G) Payment of the fine shall not constitute an admission of the violations charged; and
- (H) Respondents shall not appeal or contest the citation.

ACCEPTANCE

I have carefully read the above Stipulated Settlement for Withdrawal of Accusation and Issuance of Citation and have fully discussed it with my attorney, Ivan Petrzelka, Esq. I understand the stipulation and the effect it will have on my Pharmacy Permit No. PHY 50644. I enter into this Stipulated Settlement for Withdrawal of Accusation and Issuance of Citation

1 voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the
2 Board of Pharmacy.

3
4 DATED: _____

Signature Page Attached

GSL PHARMACY, INC., dba
PLAZA WEST PHARMACY
YELENA GOLDINA, Chief Executive Officer
Pharmacy Permit No. PHY 50644
Respondent

8
9 **ACCEPTANCE**

10 I have carefully read the above Stipulated Settlement for Withdrawal of Accusation and
11 Issuance of Citation and have fully discussed it with my attorney, Ivan Petrzelka, Esq. I
12 understand the stipulation and the effect it will have on my Pharmacist License No. RPH 51711.
13 I enter into this Stipulated Settlement for Withdrawal of Accusation and Issuance of Citation
14 voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the
15 Board of Pharmacy.

16
17 DATED: _____

YELENA GOLDINA
Pharmacist License No. RPH 51771
Respondent

20 I have read and fully discussed with Respondents Plaza West Pharmacy and Goldina the
21 terms and conditions and other matters contained in the above Stipulated Settlement for
22 Withdrawal of Accusation and Issuance of Citation. I approve its form and content.


23
24 DATED: _____

IVAN PETRZELKA
Attorney for Respondents

voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Board of Pharmacy.

DATED:

03/18/2024



GSL PHARMACY, INC., dba
PLAZA WEST PHARMACY
YELENA GOLDINA, Chief Executive Officer
Pharmacy Permit No. PHY 50644
Respondent

ACCEPTANCE

I have carefully read the above Stipulated Settlement for Withdrawal of Accusation and Issuance of Citation and have fully discussed it with my attorney, Ivan Petrzelka, Esq. I understand the stipulation and the effect it will have on my Pharmacist License No. RPH 51711. I enter into this Stipulated Settlement for Withdrawal of Accusation and Issuance of Citation voluntarily, knowingly, and intelligently, and agree to be bound by the Decision and Order of the Board of Pharmacy.

DATED:


03/18/2024


YELENA GOLDINA
Pharmacist License No. RPH 51771
Respondent

I have read and fully discussed with Respondents Plaza West Pharmacy and Goldina the terms and conditions and other matters contained in the above Stipulated Settlement for Withdrawal of Accusation and Issuance of Citation. I approve its form and content.

DATED:

March 18, 2024


IVAN PETRZELKA
Attorney for Respondents

ENDORSEMENT

The foregoing Stipulated Settlement for Withdrawal of Accusation and Issuance of Citation is hereby respectfully submitted for consideration by the Board of Pharmacy.

DATED: March 18, 2024

Respectfully submitted,

ROB BONTA
Attorney General of California
THOMAS L. RINALDI
Supervising Deputy Attorney General

Heather Vo

HEATHER VO
Deputy Attorney General
Attorneys for Complainant

LA2022604446
66650556_2.docx

**BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

CITATION AND FINE

Citation Number	Name, License No
CI 2020 91559	PLAZA WEST PHARMACY, PHY 50644

JURISDICTION: Bus. & Prof. Code § 4314; CCR, title 16, § 1775; Bus. & Prof. Code § 4301, subd. (o)

VIOLATION CODE SECTION	OFFENSE	AMT OF FINE
Bus. & Prof. Code § 4081 subd. (a)	Records of Dangerous Drugs and Devices Kept Open for Inspection; Maintenance of Records, Current Inventory	\$5,000.00

CONDUCT:

Records of Acquisition and Disposition: Business and Professions Code Section 4081 subdivision (a), in pertinent part, states all records of manufacture and of sale, acquisition, receipt, shipment, or disposition of dangerous drugs or dangerous devices shall be at all times during business hours open to inspection by authorized officers of the law, and shall be preserved for at least three years from the date of making. California Code of Regulations Section 1718, in pertinent part, states "current inventory" as used in Sections 4081 and 4332 of the Business and Professions Code shall be considered to include complete accountability for all dangerous drugs handled by every licensee enumerated in Sections 4081 and 4332. Specifically, an audit for the period between 01/01/2020 and 12/30/2021 of Plaza West Pharmacy, PHY50644, located at 8540 Sepulveda Boulevard #102, Los Angeles, CA 90045, revealed an overage (sold more than purchased) of Creon Dr 24,000 units capsule, Dexilant Dr 60 mg capsule, Vascepa 1 gm capsule, Xarelto 15 mg tablet and Xarelto 20 mg tablet.

The lack of accurate records for the disposed medications, as evidenced by the overages found, is a violation of Business and Professions Code 4081(a) and California Code of Regulations Section 1718.

CITATION ISSUED ON: June 27, 2024

TOTAL AMOUNT OF FINE(S): \$5,000.00

PAYMENT OF FINE(S) DUE BY: July 27, 2024

**BOARD OF PHARMACY
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA**

CITATION AND FINE

Citation Number	Name, License No
CI 2023 104924	YELENA GOLDINA , RPH 51771

JURISDICTION: Bus. & Prof. Code § 4314; CCR, title 16, § 1775; Bus. & Prof. Code § 4113 subd. (c) Bus. & Prof. Code § 4301, subd. (o)

VIOLATION CODE SECTION	OFFENSE	AMT OF FINE
Bus. & Prof. Code § 4081 subd. (a)	Records of Dangerous Drugs and Devices Kept Open for Inspection; Maintenance of Records, Current Inventory	\$5,000.00

CONDUCT:

Records of Acquisition and Disposition: Business and Professions Code Section 4081 subdivision (a), in pertinent part, states all records of manufacture and of sale, acquisition, receipt, shipment, or disposition of dangerous drugs or dangerous devices shall be at all times during business hours open to inspection by authorized officers of the law, and shall be preserved for at least three years from the date of making. California Code of Regulations Section 1718, in pertinent part, states “current inventory” as used in Sections 4081 and 4332 of the Business and Professions Code shall be considered to include complete accountability for all dangerous drugs handled by every licensee enumerated in Sections 4081 and 4332.

Specifically, an audit for the period between 01/01/2020 and 12/30/2021 of Plaza West Pharmacy, PHY50644, located at 8540 Sepulveda Boulevard #102, Los Angeles, CA 90045, revealed an overage (sold more than purchased) of Creon Dr 24,000 units capsule, Dexilant Dr 60 mg capsule, Vascepa 1 gm capsule, Xarelto 15 mg tablet and Xarelto 20 mg tablet. Yelena Goldina, RPH51771, was acting as the pharmacist-in-charge of Plaza West Pharmacy, PHY50644, during the audit period.

The lack of accurate records for the disposed medications, as evidenced by the overages found, is a violation of Business and Professions Code 4081(a) and California Code of Regulations Section 1718.

CITATION ISSUED ON: June 27, 2024	TOTAL AMOUNT OF FINE(S): \$5,000.00
--	--

PAYMENT OF FINE(S) DUE BY: July 27, 2024

Exhibit A

Accusation Case No. 7431

1 ROB BONTA
Attorney General of California
2 THOMAS L. RINALDI
Supervising Deputy Attorney General
3 HEATHER VO
Deputy Attorney General
4 State Bar No. 223418
300 So. Spring Street, Suite 1702
5 Los Angeles, CA 90013
Telephone: (213) 269-6317
6 Facsimile: (916) 731-2126
Attorneys for Complainant
7

8 **BEFORE THE**
9 **BOARD OF PHARMACY**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 7431

13 **GSL PHARMACY, INC., dba**
14 **PLAZA WEST PHARMACY**
15 **YELENA GOLDINA, Chief Executive Officer**
16 **8540 Sepulveda Blvd, #102**
17 **Los Angeles, CA 90045**

ACCUSATION

18 **Pharmacy Permit No. PHY 50644**

19 **and**

20 **YELENA GOLDINA**
21 **8540 Sepulveda Blvd., #102**
22 **Los Angeles, CA 91436**

23 **Pharmacist License No. RPH 51771**

24 Respondents.

25 **PARTIES**

26 1. Anne Sodergren (Complainant) brings this Accusation solely in her official capacity
27 as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.

28 **Pharmacy Permit**

1 On or about June 9, 2011, the Board of Pharmacy issued Pharmacy Permit Number
2 PHY 50644 to GSL Pharmacy, Inc., doing business as Plaza West Pharmacy, Yelena Goldina as

1 Chief Executive Officer (Respondent Plaza West Pharmacy). The Pharmacy Permit was in full
2 force and effect at all times relevant to the charges brought herein and will expire on June 1,
3 2023, unless renewed.

4 Pharmacist License

5 3. On or about August 29, 2000, the Board of Pharmacy issued Pharmacist License
6 Number RPH 51771 to Yelena Goldina (Respondent Goldina). The Pharmacist License was in
7 full force and effect at all times relevant to the charges brought herein and will expire on July 31,
8 2024, unless renewed. Respondent Goldina has been the Pharmacist-in-Charge of Respondent
9 Plaza West Pharmacy since October 1, 2013.

10 **JURISDICTION**

11 4. This Accusation is brought before the Board of Pharmacy, Department of Consumer
12 Affairs (Board), under the authority of the following laws. All section references are to the
13 Business and Professions Code (Code) unless otherwise indicated.

14 5. Section 4011 of the Code provides that the Board shall administer and enforce both
15 the Pharmacy Law [Bus. & Prof. Code, § 4000 et seq.] and the Uniform Controlled Substances
16 Act [Health & Safety Code, § 11000 et seq.].

17 6. Section 4300, subdivision (a) of the Code provides that every license issued by the
18 Board may be suspended or revoked.

19 7. Section 4300.1 of the Code states:

20 The expiration, cancellation, forfeiture, or suspension of a board-issued license
21 by operation of law or by order or decision of the board or a court of law, the
22 placement of a license on a retired status, or the voluntary surrender of a license by a
23 licensee shall not deprive the board of jurisdiction to commence or proceed with any
investigation of, or action or disciplinary proceeding against, the licensee or to render
a decision suspending or revoking the license.

24 **STATUTORY PROVISIONS**

25 8. Section 4022 of the Code states

26 "Dangerous drug" or "dangerous device" means any drug or device unsafe
27 for self-use in humans or animals, and includes the following:

28 (a) Any drug that bears the legend: "Caution: federal law prohibits dispensing
without prescription," "Rx only," or words of similar import.

1 (b) Any device that bears the statement: "Caution: federal law restricts this
2 device to sale by or on the order of a _____" "Rx only," or words of similar import, the
3 blank to be filled in with the designation of the practitioner licensed to use or order
4 use of the device.

5 (c) Any other drug or device that by federal or state law can be lawfully
6 dispensed only on prescription or furnished pursuant to Section 4006.

7 9. Section 4081 of the Code states:

8 (a) All records of manufacture and of sale, acquisition, or disposition of
9 dangerous drugs or dangerous devices shall be at all times during business hours open
10 to inspection by authorized officers of the law, and shall be preserved for at least
11 three years from the date of making. A current inventory shall be kept by every
12 manufacturer, wholesaler, pharmacy, veterinary food-animal drug retailer, physician,
13 dentist, podiatrist, veterinarian, laboratory, clinic, hospital, institution, or
14 establishment holding a currently valid and unrevoked certificate, license, permit,
15 registration, or exemption under Division 2 (commencing with Section 1200) of the
16 Health and Safety Code or under Part 4 (commencing with Section 16000) of
17 Division 9 of the Welfare and Institutions Code who maintains a stock of dangerous
18 drugs or dangerous devices.

19 (b) The owner, officer, and partner of any pharmacy, wholesaler, or veterinary
20 food-animal drug retailer shall be jointly responsible, with the pharmacist-in-charge
21 or representative-in-charge, for maintaining the records and inventory described in
22 this section.

23 (c) The pharmacist-in-charge or representative-in-charge shall not be criminally
24 responsible for acts of the owner, officer, partner, or employee that violate this
25 section and of which the pharmacist-in-charge or representative-in-charge had no
26 knowledge, or in which he or she did not knowingly participate.

27 10. Section 4105 of the Code states:

28 (a) All records or other documentation of the acquisition and disposition of
dangerous drugs and devices by any entity licensed by the board shall be retained on
the licensed premises in a readily retrievable form.

... (c) The records required by this section shall be retained on the licensed premises for
a period of three years from the date of making.

11. Section 4113, subdivision (c) of the Code states:

The pharmacist-in-charge shall be responsible for a pharmacy's compliance
with all state and federal laws, and regulations pertaining to the practice of pharmacy.

12. Section 4301 of the Code states in pertinent part:

The board shall take action against any holder of a license who is guilty of
unprofessional conduct or whose license has been issued by mistake. Unprofessional
conduct shall include, but is not limited to, any of the following:

... (o) Violating or attempting to violate, directly or indirectly, or assisting in or

abetting the violation of or conspiring to violate any provision or term of this chapter or of the applicable federal and state laws and regulations governing pharmacy, including regulations established by the board or any other state or federal regulatory agency.

...

13. Section 4307, subdivision (a) of the Code states:

Any person who has been denied a license or whose license has been revoked or is under suspension, or who has failed to renew his or her license while it was under suspension, or who has been a manager, administrator, owner member, officer, director, associate, or partner of any partnership, corporation, firm, or association whose application for a license has been denied or revoked, is under suspension or has been placed on probation, and while acting as the manger, administrator, owner, member, officer, director, associate, or partner had knowledge or knowingly participated in any conduct for which the license was denied, revoked, suspended, or placed on probation, shall be prohibited from serving as a manger, administrator, owner, member, officer, director, associate, or partner of a licensee as follows:

(1) Where a probationary license is issued or where an existing license is placed on probation, this prohibition shall remain in effect for a period not to exceed five years.

(2) Where the license is denied or revoked, the prohibition shall continue until the license is issued or reinstated.

14. Section 4332 of the Code states:

Any person who fails, neglects, or refuses to maintain the records required by Section 4081 or who, when called upon by an authorized officer or a member of the board, fails, neglects, or refuses to produce or provide the records within a reasonable time, or who willfully produces or furnishes records that are false, is guilty of a misdemeanor.

REGULATORY PROVISIONS

15. California Code of Regulations, title 16, section 1718, states in pertinent part:

“Current Inventory” as used in Sections 4081 and 4332 of the Business and Professions Code shall be considered to include complete accountability for all dangerous drugs handled by every licensee enumerated in Sections 4081 and 4332.

COST RECOVERY

16. Section 125.3 of the Code provides, in pertinent part, that the Board may request the administrative law judge to direct a licentiate found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case.

///

///

DRUGS

17. Creon Dr is a brand brand name for pancrelipase and a dangerous drug pursuant to Business and Professions Code section 4022. It is used for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

18. Dexilant is a brand name for dexlansoprazole and a dangerous drug pursuant to Business and Professions Code section 4022. It is used for the treatment of stomach and esophagus problems such as acid reflux.

19. Vascepa is a brand name for icosapent ethyl and a dangerous drug pursuant to Business and Professions Code section 4022. It is used for the treatment of reducing triglycerides (fats).

20. Xarelto is a brand name for rivaroxaban and a dangerous drug pursuant to Business and Professions Code section 4022. It is used to treat and prevent dangerous blood clots in the body.

FACTUAL ALLEGATIONS

21. Respondent Plaza West Pharmacy is located in Los Angeles, California. At all times relevant herein, Respondent Goldina was the Pharmacist-in-Charge and Chief Executive Officer of Plaza West Pharmacy.

22. On or around April 18, 2021, the Board received a complaint from Qlarant, a Medicare Drug Integrity Contractor (I-MEDIC), alleging several drug overages at Respondent Plaza West Pharmacy¹. I-MEDIC is contracted by the Centers for Medicare & Medicaid Services to conduct investigations into fraud, waste and abuse in the Medicare Parts C and D Programs. During the course of the investigation, it was determined that Respondent Plaza West Pharmacy failed to maintain proper records of acquisition and disposition of dangerous drugs.

23. On December 30, 2021, a Board inspection was conducted at Respondent Plaza West Pharmacy with the assistance of Respondent Goldina. The Board performed an audit for medications dispensed between January 1, 2020 and December 30, 2021 for the following drugs:

¹ Drug overages are defined as the pharmacy selling more drugs than it purchased.

1 Creon Dr 24,000 units capsule, Dexilant Dr 60 mg capsule, Vascepa 1 gm capsule, Xarelto 15 mg
2 tablet, and Xarelto 20 mg tablet.

3 24. The Board reviewed the pharmacy's dispensing records, stock on hand, and
4 wholesaler records. Based on the evidence collected, the audit revealed that Respondent Plaza
5 West Pharmacy sold a greater amount of medication than it purchased with respect to each of the
6 aforementioned drugs, resulting in an overpayment by insurance providers to Respondent Plaza
7 West Pharmacy in approximately \$445,706.54.

8 **FIRST CAUSE FOR DISCIPLINE**

9 **(Failure to Maintain Current Inventory)**

10 25. Respondents Plaza West Pharmacy and Goldina are subject to disciplinary action
11 under Code section 4301, subdivision (o), for violating Code sections 4081, subdivision (a), and
12 4332, and California Code of Regulations, title 16, section 1718, in that they did not maintain a
13 current inventory of dangerous drugs. Complainant refers to, and by this reference incorporates,
14 the allegations set forth above in paragraphs 21 through 24, inclusive, as though set forth fully
15 herein.

16 **SECOND CAUSE FOR DISCIPLINE**

17 **(Failure to Maintain Records)**

18 26. Respondents Plaza West Pharmacy and Goldina are subject to disciplinary action
19 under Code section 4301, subdivision (o), for violating Code sections 4081, subdivision (a), and
20 4105, subdivisions (a) and (c), and California Code of Regulations, title 16, section 1718, in that
21 they did not maintain records of dangerous drugs. Complainant refers to, and by this reference
22 incorporates, the allegations set forth above in paragraphs 21 through 24, inclusive, as though set
23 forth fully herein.

24 **THIRD CAUSE FOR DISCIPLINE**

25 **(Unprofessional Conduct)**

26 27. Respondents Plaza West Pharmacy and Goldina are subject to disciplinary action
27 under Code section 4301, in that Respondents committed acts of unprofessional conduct.
28

1 Complainant refers to, and by this reference incorporates, the allegations set forth above in
2 paragraphs 21 through 24, inclusive, as though set forth fully herein.

3 **OTHER MATTERS**

4 28. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number
5 PHY 50644 issued to GSL Pharmacy, Inc. doing business as Plaza West Pharmacy, it shall be
6 prohibited from serving as a manager, administrator, owner, member, officer, director, associate,
7 or partner of a licensee for five years if Pharmacy Permit Number PHY 50644 is placed on
8 probation or until Pharmacy Permit Number PHY 50644 is reinstated if it is revoked.

9 29. Pursuant to Code section 4307, if discipline is imposed on Pharmacy Permit Number
10 PHY 50644 issued to GSL Pharmacy, Inc. doing business as Plaza West Pharmacy, while Yelena
11 Goldina has been an owner or manager and had knowledge of or knowingly participated in any
12 conduct for which the licensee was disciplined, Yelena Goldina shall be prohibited from serving
13 as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee
14 for five years if Pharmacy Permit Number PHY 50644 is placed on probation or until Pharmacy
15 Permit Number PHY 50644 is reinstated if it is revoked.

16 30. Pursuant to Code section 4307, if discipline is imposed on Pharmacist License No.
17 RPH 51771 issued to Yelena Goldina, Yelena Goldina shall be prohibited from serving as a
18 manager, administrator, owner, member, officer, director, associate, or partner of a licensee for
19 five years if Pharmacist License Number RPH 51771 is placed on probation or until Pharmacist
20 License Number RPH 51771 is reinstated if it is revoked.

21 **PRAYER**

22 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
23 and that following the hearing, the Board of Pharmacy issue a decision:

24 1. Revoking or suspending Pharmacy Permit Number PHY 50644, issued to GSL
25 Pharmacy, Inc., dba Plaza West Pharmacy; Yelena Goldina as the Chief Executive Officer;

26 2. Revoking or suspending Pharmacist License Number RPH 51771, issued to Yelena
27 Goldina;

1 3. Prohibiting GSL Pharmacy, Inc., dba Plaza West Pharmacy from serving as a
2 manager, administrator, owner, member, officer, director, associate, or partner of a licensee for
3 five years if Pharmacy Permit Number PHY 50644 is placed on probation or until Pharmacy
4 Permit Number PHY 50644 is reinstated if Pharmacy Permit Number PHY 50644 issued to GSL
5 Pharmacy, Inc., dba Plaza West Pharmacy is revoked;

6 4. Prohibiting Yelena Goldina from serving as a manager, administrator, owner, member,
7 officer, director, associate, or partner of a licensee for five years if Pharmacy Permit Number PHY
8 50644 is placed on probation or until Pharmacy Permit Number PHY 50644 is reinstated if Pharmacy
9 Permit Number PHY 50644 issued to GSL Pharmacy, Inc., dba Plaza West Pharmacy is revoked;

10 5. Prohibiting Yelena Goldina from serving as a manager, administrator, owner,
11 member, officer, director, associate, or partner of a licensee for five years if Pharmacist Number
12 RPH 51771 is placed on probation or until Pharmacist License Number RPH 51771 is reinstated
13 if Pharmacist License Number RPH 51771 is revoked;

14 6. Ordering Respondents to pay the Board of Pharmacy the reasonable costs of the
15 investigation and enforcement of this case, pursuant to Business and Professions Code section
16 125.3; and,

17 7. Taking such other and further action as deemed necessary and proper.

18
19
20 DATED: 4/15/2023

Sodergren,
Anne@DCA

Digitally signed by Sodergren,
Anne@DCA
Date: 2023.04.15 07:06:51
-07'00'

ANNE SODERGREN
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

21
22
23
24
25
26
27 LA2022604446
65805872_2.docx